IDYA IDEAYA Biosciences, Inc. Forward P/S Multiple

IDEAYA Biosciences (IDYA) is advancing precision oncology by developing genetically engineered therapies to target rare mutations. The forward P/S trend demonstrates the effectiveness of its synthetic lethality platform and partnerships with pharmaceutical behemoths, with 83.40 representing the current metric. The asset's price action remains independent of macro cycles, relying exclusively on clinical trial results and partnership payments.

IDYA (ideayabio.com) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

IDEAYA Corp - analytical breakdowns and key metrics (IDYA)

- current price and projected stock value:

Stock Price IDEAYA Biosciences, Inc.|IDYA - Analyst Target Range

- market capitalization data:

Market Capitalization IDEAYA Corp|IDYA - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share IDEAYA Biosciences|IDYA - Total Net Assets|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Company Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

IDYA - Company Net Income|Expected Profit IDEAYA Biosciences|IDYA - Company Value to Net Income|Forward P/E Multiple IDEAYA Bio|IDYA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization IDEAYA Corp|IDYA - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months IDEAYA Biosciences|IDYA - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth ideayabio.com|IDYA - Expected net earnings per share growth this year|Earnings growth forecast for next year IDEAYA Biosciences

- issuer revenue and sales details:

IDYA - Company Sales Volume|Projected Sales Volume IDEAYA Biosciences, Inc.|IDYA - Price to Sales|Forward P/S Multiple IDEAYA Corp

Summary company analysis:IDEAYA Biosciences, Inc. (IDYA)

The forward P/S ratio relates the current market capitalization of IDEAYA Biosciences (IDYA) to expected annual revenues, reflecting market expectations for the commercialization of precision oncology drugs. By analyzing the forward P/S trend, an investor can see the valuation's sensitivity to clinical phase successes and partnerships, where any increase in the multiple heightens the risk of a correction should financing issues arise or research trials fail.

Competing companies